

# Third annual meeting in the Danish Biobank Network

## Thursday 18 January 2018

### Programme:

- 10:00 Welcome by Lasse Boding, Coordinator, Danish National Biobank
- 10:10 National guidelines for public-private partnerships (PPP) by Lasse Boding, Coordinator, Danish National Biobank
- 10:20 Evaluation of suppliers– Novo Nordisk’s approach to responsible sourcing of human biosamples by Brian Clark, Senior Director, Novo Nordisk
- 10:40 Healthcare DENMARK, Danish health and PPP in an international context by Hans Erik Henriksen, CEO, Healthcare DENMARK
- 11:00 Pre-competitive collaboration between biobanks and industry by Christian Jonasson, Senior Researcher, Norwegian University of Science and Technology
- 11:20 Medicon Valley Alliance – the Danish-Swedish life science hub for PPP by Petter Hartman, CEO, Medicon Valley Alliance
- 11:40 Discussion
- 12:00 Lunch
- 13:00 GWAS in the Danish Blood Donor Study – an example of a large-scale PPP by Christian Erikstrup, Professor, Aarhus University Hospital
- 13:20 Three local cases from the Department of Molecular Medicine (MOMA) at Aarhus University Hospital:
- Prostate cancer biomarker development by Siri Strand, Postdoc, Prostate Cancer Research Group
  - Circulating tumor DNA as a marker for monitoring residual disease after colon cancer surgery by Claus Lindbjerg Andersen, Professor, Colorectal Cancer Research Group
  - Blood and urine samples for monitoring aggressiveness, disease relapse and treatment response in bladder cancer by Lars Dyrskjøt Andersen, Professor, Bladder Cancer Research Group
- 14:20 5 min biobank updates on new resources, initiatives and facilities
- 15:00 Closing remarks

### Place:

Dept. of Molecular Medicine (MOMA)  
Aarhus University Hospital  
Science Center Skejby  
Brendstrupgårdsvej 21A  
8200 Aarhus N

In the auditorium at the ground floor (main entrance)

### Registration:

Before 10 January 2018 to [labo@ssi.dk](mailto:labo@ssi.dk)

